Review of the Delay of Chronic Kidney Disease Progression by Wuling San on Improving Renal Fibrosis

IF 2.7 4区医学 Q2 PHARMACOLOGY & PHARMACY

Basic & Clinical Pharmacology & Toxicology Pub Date : 2025-06-30 DOI:10.1111/bcpt.70071

Zhijun Zeng, Beini Lao, Ke Liu, Yiwen Cao, Yongan Liao, Jiuyao Zhou

{"title":"Review of the Delay of Chronic Kidney Disease Progression by Wuling San on Improving Renal Fibrosis","authors":"Zhijun Zeng, Beini Lao, Ke Liu, Yiwen Cao, Yongan Liao, Jiuyao Zhou","doi":"10.1111/bcpt.70071","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Renal fibrosis is a common pathological process in chronic kidney disease (CKD), which is mainly characterized by glomerulosclerosis and tubulointerstitial fibrosis. The formation and development of renal fibrosis are stimulated by pro-inflammatory as well as pro-fibrosis factors released by inflammatory cells. Wuling San is an ancient Chinese classical formula for urination-promoting and dampness-draining, which can regulate the metabolism of water and fluid and has exerted therapeutic effects on various chronic kidney diseases by reducing oedema, inflammation, and improving glomerulosclerosis and renal interstitial fibrosis. However, further study is still needed to explore the mechanism. Based on the research analysis with the help of CiteSpace, the following three directions were the possible mechanisms in improving renal fibrosis: inhibiting the conversion of renal cells to myofibroblasts; regulating amino acid, lipid and energy metabolism and reducing extracellular matrix (ECM) deposition; and regulating the RhoA/ROCK pathway, the downstream of G protein-coupled receptor (GPCR). This review aims to summarize the mechanism of action of Wuling San in the treatment of CKD from the perspective of antifibrosis, which can help to explore the new ideas and directions of Wuling San in the treatment of renal diseases.</p>\n </section>\n </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 2","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70071","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic & Clinical Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bcpt.70071","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Renal fibrosis is a common pathological process in chronic kidney disease (CKD), which is mainly characterized by glomerulosclerosis and tubulointerstitial fibrosis. The formation and development of renal fibrosis are stimulated by pro-inflammatory as well as pro-fibrosis factors released by inflammatory cells. Wuling San is an ancient Chinese classical formula for urination-promoting and dampness-draining, which can regulate the metabolism of water and fluid and has exerted therapeutic effects on various chronic kidney diseases by reducing oedema, inflammation, and improving glomerulosclerosis and renal interstitial fibrosis. However, further study is still needed to explore the mechanism. Based on the research analysis with the help of CiteSpace, the following three directions were the possible mechanisms in improving renal fibrosis: inhibiting the conversion of renal cells to myofibroblasts; regulating amino acid, lipid and energy metabolism and reducing extracellular matrix (ECM) deposition; and regulating the RhoA/ROCK pathway, the downstream of G protein-coupled receptor (GPCR). This review aims to summarize the mechanism of action of Wuling San in the treatment of CKD from the perspective of antifibrosis, which can help to explore the new ideas and directions of Wuling San in the treatment of renal diseases.

Abstract Image

查看原文本刊更多论文

五灵散改善肾纤维化延缓慢性肾病进展的研究进展

肾纤维化是慢性肾脏疾病（CKD）常见的病理过程，主要表现为肾小球硬化和小管间质纤维化。促炎因子和促纤维化因子均可刺激肾纤维化的形成和发展。五灵散是中国古代经典的化尿湿泻方，具有调节水、液代谢，减轻水肿、炎症、改善肾小球硬化和肾间质纤维化等作用，对各种慢性肾脏疾病均有治疗作用。但其作用机制仍需进一步研究。基于CiteSpace的研究分析，认为改善肾纤维化的可能机制有以下三个方向：抑制肾细胞向肌成纤维细胞的转化；调节氨基酸、脂质和能量代谢，减少细胞外基质（ECM）沉积；调控G蛋白偶联受体（GPCR）下游RhoA/ROCK通路。本文拟从抗纤维化角度对五灵散治疗CKD的作用机制进行综述，有助于探索五灵散治疗肾脏疾病的新思路和新方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Basic & Clinical Pharmacology & Toxicology 医学-毒理学

CiteScore

5.60

自引率

6.50%

发文量

126

审稿时长

1 months

期刊介绍： Basic & Clinical Pharmacology and Toxicology is an independent journal, publishing original scientific research in all fields of toxicology, basic and clinical pharmacology. This includes experimental animal pharmacology and toxicology and molecular (-genetic), biochemical and cellular pharmacology and toxicology. It also includes all aspects of clinical pharmacology: pharmacokinetics, pharmacodynamics, therapeutic drug monitoring, drug/drug interactions, pharmacogenetics/-genomics, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, randomized controlled clinical trials and rational pharmacotherapy. For all compounds used in the studies, the chemical constitution and composition should be known, also for natural compounds.